Angiogenesis as risk factor for plaque vulnerability

Current Pharmaceutical Design

Volumn 15, Issue 10, 2009, Pages 1095-1106

  Di Stefano, Rossella ^a   Felice, Francesca ^a   Balbarini, Alberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Angiogenesis; Atherosclerosis; Intraplaque neovascularization; Plaque vulnerability

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CANSTATIN; CHEMOKINE; CHOLESTEROL; COMBRETASTATIN A4; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PHOSPHOLIPID; PRINOMASTAT; RESTIN; SEMAXANIB; SIMVASTATIN; SURAMIN; THALIDOMIDE; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VATSTATIN;

ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; ERYTHROCYTE; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INFLAMMATION; INTRAVASCULAR ULTRASOUND; MACROPHAGE; MORPHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ERYTHROID PRECURSOR CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS;

EID: 65649133559     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846892     Document Type: Review

References (143)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-20.
2. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: II27-33.
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-19.
4. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
5. Davies MJ. The composition of coronary-artery plaques. N Engl J Med 1997; 336: 1312-4.
6. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, et al. Platelet-endothelial cell interactions during ischemia/ reperfusion: the role of P-selectin. Blood 1998; 92: 507- 15.
7. O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145: 883-94.
8. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol 1999; 188: 189-96.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
10. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
11. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006; 59: 15-26.
12. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437: 497-504.
13. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
14. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801-6.
15. Kolodgie FD, Narula J, Yuan C, Burke AP, Finn AV, Virmani R. Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J Am Coll Cardiol 2007; 49: 2093-101.
16. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49: 2073-80.
17. Imparato AM, Riles TS, Mintzer R, Baumann FG. The importance of hemorrhage in the relationship between gross morphologic characteristics and cerebral symptoms in 376 carotid artery plaques. Ann Surg 1983; 197: 195-203.
18. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005; 25: 2054-61.
19. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart 2004; 90: 1385-91.
20. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
21. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 4736-41.
22. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
23. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 4- 11.
24. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
25. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Jr, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462-78.
26. Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97: 2307-15.
27. Gerrity RG. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 1981; 103: 191-200.
28. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta 2000; 1529: 164-74.
29. Tabas I, Marathe S, Keesler GA, Beatini N, Shiratori Y. Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis. Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis. J Biol Chem. 1996; 271: 22773-81.
30. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
31. Rao DS, Goldin JG, Fishbein MC. Determinants of plaque instability in atherosclerotic vascular disease. Cardiovasc Pathol 2005; 14: 285-93.
32. Kockx MM, Cromheeke KM, Knaapen MW, Bosmans JM, De Meyer GR, Herman AG, et al. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 440-6.
33. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
34. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
35. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004; 110: 2032-8. 36 Russell DA, Abbott CR, Gough MJ. Vascular endothelial growth factor is associated with histological instability of carotid plaques. Br J Surg 2008; 95: 576-81.
36. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 2004; 25: 1077-82.
37. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
38. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20.
39. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 1993; 87: 1179-87.
40. Tofler GH, Stone PH, Maclure M, Edelman E, Davis VG, Robertson T, et al. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 1990; 66: 22-7.
41. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15: 1512-31.
42. Barger AC, Beeuwkes R, 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-7.
43. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR, Jr, Schwartz RS, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-6.
44. Kaiser M, Younge B, Bjornsson J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999; 155: 765-74.
45. Heistad DD, Armstrong ML. Blood flow through vasa vasorum of coronary arteries in atherosclerotic monkeys. Arteriosclerosis 1986; 6: 326-31.
46. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol 1993; 143: 164-72.
47. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995; 26: 450-6.
48. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 2004; 110: 2843-50.
49. Moulton KS. Plaque angiogenesis: its functions and regulation. Cold Spring Harb Symp Quant Biol 2002; 67: 471-82.
50. Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. Immunohistochemical expression of vascular endothelial growth factor/ vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol 1999; 19: 131-9.
51. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999; 41: 443-9.
52. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-78.
53. Gossl M, Beighley PE, Malyar NM, Ritman EL. Role of vasa vasorum in transendothelial solute transport in the coronary vessel wall: a study with cryostatic micro-CT. Am J Physiol Heart Circ Physiol 2004; 287: H2346-51.
54. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-93.
55. Ren G, Michael LH, Entman ML, Frangogiannis NG. Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem 2002; 50: 71-9.
56. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999; 30: 261-8.
57. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 2005; 111: 2768-75.
58. Dunmore BJ, McCarthy MJ, Naylor AR, Brindle NP. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg 2007; 45: 155-9.
59. Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta 1985; 822: 267-87.
60. Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol 2007; 49: 2081-9.
61. Heinecke JW. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radic Biol Med 2002; 32: 1090-101.
62. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879-91.
63. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365-77.
64. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-9.
65. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274: 11924-9.
66. Bjornheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 870-6.
67. Kuwahara F, Kai H, Tokuda K, Shibata R, Kusaba K, Tahara N, et al. Hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension 2002; 39: 46-50.
68. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004; 109: 520-5.
69. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
70. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF, Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 1993; 92: 2408-18.
71. Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997; 150: 1673-85.
72. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
73. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007; 18: 492-9.
74. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-6.
75. Leroyer AS, Rautou PE, Silvestre JS, Castier Y, Leseche G, Devue C, et al. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol 2008; 52: 1302-11.
76. Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 2001; 3: 225-33.
77. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-50.
78. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-9.
79. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
80. Ma H, Calderon TM, Fallon JT, Berman JW. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis 2002; 164: 79-87.
81. Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, Rezaie-Majd S, Korschineck I, Schleef RR, et al. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol 1999; 19: 2340-7.
82. Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol 2000; 192: 234-42.
83. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
84. Yan J, Wu Z, Huang Z, Li L, Zhong R, Kong X. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J (Engl) 2002; 115: 491-3.
85. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000 Dec 1; 96: 3801-8.
86. Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 2003; 171: 1534-41.
87. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49: 772-7.
88. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
89. Morel O, Toti F, Bakouboula B, Grunebaum L, Freyssinet JM. Procoagulant microparticles: 'criminal partners' in atherothrombosis and deleterious cellular exchanges. Pathophysiol Haemost Thromb 2006; 35: 15-22.
90. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005; 20: 22-7.
91. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
92. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
93. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-6.
94. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
95. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med 2005; 56: 79-101.
96. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 2006; 26: 1008-14.
97. Sueishi K, Yonemitsu Y, Nakagawa K, Kaneda Y, Kumamoto M, Nakashima Y. Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann N Y Acad Sci 1997; 811: 311-22; 22-4.
98. Wilson SH, Herrmann J, Lerman LO, Holmes DR, Jr, Napoli C, Ritman EL, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-8.
99. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002; 8: 607-12.
100. Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 2003; 108: 3122-7.
101. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-7.
102. Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002; 8: 1004-10.
103. Vasa M, FichtIscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
104. Xiao Q, Kiechl S, Patel S, Oberhollenzer F, Weger S, Mayr A, et al. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis--results from a large population-based study. PLoS ONE 2007; 2: e975.
105. Guven H, Shepherd RM, Bach RG, Capoccia BJ, Link DC. The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. J Am Coll Cardiol 2006; 48: 1579-87.
106. George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 2636-41.
107. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-9.
108. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, et al. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7: 738-41.
109. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci USA 2003; 100: 4754-9.
110. Zoll J, Fontaine V, Gourdy P, Barateau V, Vilar J, Leroyer A, et al. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. Cardiovasc Res 2008; 77: 471-80.
111. Hu Y, Davison F, Ludewig B, Erdel M, Mayr M, Url M, et al. Smooth muscle cells in transplant atherosclerotic lesions are originated from recipients, but not bone marrow progenitor cells. Circulation 2002; 106: 1834-9.
112. Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003; 107: 851-6.
113. Feinstein SB. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J Am Coll Cardiol 2006; 48: 236-43.
114. Sirlin CB, Lee YZ, Girard MS, Peterson TM, Steinbach GC, Baker KG, et al. Contrast-enhanced B-mode US angiography in the assessment of experimental in vivo and in vitro atherosclerotic disease. Acad Radiol 2001; 8: 162-72.
115. Kono Y, Pinnell SP, Sirlin CB, Sparks SR, Georgy B, Wong W, et al. Carotid arteries: contrast-enhanced US angiography-preliminary clinical experience. Radiology 2004; 230: 561-8.
116. Wong M, Edelstein J, Wollman J, Bond MG. Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. Arterioscler Thromb 1993; 13: 482-6.
117. Rajaram V, Pandhya S, Patel S, Meyer PM, Goldin M, Feinstein MJ, et al. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 2004; 93: 32C-48C.
118. Vicenzini E, Giannoni MF, Puccinelli F, Ricciardi MC, Altieri M, Di Piero V, et al. Detection of carotid adventitial vasa vasorum and plaque vascularization with ultrasound cadence contrast pulse sequencing technique and echo-contrast agent. Stroke 2007; 38: 2841-3.
119. Huang PT, Huang FG, Zou CP, Sun HY, Tian XQ, Yang Y, et al. Contrast-enhanced sonographic characteristics of neovascularization in carotid atherosclerotic plaques. J Clin Ultrasound 2008; 36: 346-51.
120. Shah F, Balan P, Weinberg M, Reddy V, Neems R, Feinstein M, et al. Contrast-enhanced ultrasound imaging of atherosclerotic carotid plaque neovascularization: a new surrogate marker of atherosclerosis? Vasc Med 2007; 12: 291-7.
121. Coli S, Magnoni M, Sangiorgi G, Marrocco-Trischitta MM, Melisurgo G, Mauriello A, et al. Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity. J Am Coll Cardiol 2008; 52: 223-30.
122. Carlier S, Kakadiaris IA, Dib N, Vavuranakis M, O'Malley SM, Gul K, et al. Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Atheroscler Rep 2005; 7: 164-9.
123. Goertz DE, Frijlink ME, de Jong N, van der Steen AF. Nonlinear intravascular ultrasound contrast imaging. Ultrasound Med Biol 2006; 32: 491-502.
124. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004; 350: 1472-3.
125. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-32.
126. Jain RK. Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
127. Kampschulte A, Ferguson MS, Kerwin WS, Polissar NL, Chu B, Saam T, et al. Differentiation of intraplaque versus juxtaluminal hemorrhage/ thrombus in advanced human carotid atherosclerotic lesions by in vivo magnetic resonance imaging. Circulation 2004; 110: 3239-44.
128. Chen WQ, Zhang M, Ji XP, Ding SF, Zhao YX, Chen YG, et al. Usefulness of high-frequency vascular ultrasound imaging and serum inflammatory markers to predict plaque rupture in patients with stable and unstable angina pectoris. Am J Cardiol 2007; 100: 1341-6.
129. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumours follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-65.
130. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002; 21: 1939-47.
131. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein Edeficient mice. Circulation 1999; 99: 1726-32.
132. Stefanadis C, Toutouzas K, Stefanadi E, Kolodgie F, Virmani R, Kipshidze N. First experimental application of bevacizumabeluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 2006; 47: 7-10.
133. Jain RK. Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
134. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648- 57.
135. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36: 150-7.
136. Koutouzis M, Nomikos A, Nikolidakis S, Tzavara V, Andrikopoulos V, Nikolaou N, et al. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 2007; 192: 457-63.
137. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
138. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
139. Moulton KS. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol 2006; 17: 548-55.
140. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70.
141. Passacquale G, Tiberti S, Ferri C, Desideri G. Morphology of atherosclerotic plaque: its feature by imaging study. Curr Pharm Des 2008; 14(18): 1753-60.
142. Shiba Y, Takahashi M, Ikeda U. Models for the study of angiogenesis. Curr Pharm Des 2008; 14(4): 371-7.
143. Vannini N, Pfeffer U, Lorusso G, Noonan DM, Albini A. Endothelial cell aging and apoptosis in prevention and disease: E-selectin expression and modulation as a model. Curr Pharm Des 2008; 14(3): 221-5.